Literature DB >> 16306430

Lesional overexpression of matrix metalloproteinase-9 promotes intraplaque hemorrhage in advanced lesions but not at earlier stages of atherogenesis.

R de Nooijer1, C J N Verkleij, J H von der Thüsen, J W Jukema, E E van der Wall, Thüsen J C van Berkel, A H Baker, E A L Biessen.   

Abstract

BACKGROUND: Matrix metalloproteinase-9 (MMP-9) is involved in atherosclerosis and elevated MMP-9 activity has been found in unstable plaques, suggesting a crucial role in plaque rupture. This study aims to assess the effect of MMP-9 on plaque stability in apolipoprotein E-deficient mice at different stages of plaque progression. METHODS AND
RESULTS: Atherosclerotic lesions were elicited in carotid arteries by perivascular collar placement. MMP-9 overexpression in intermediate or advanced plaques was effected by intraluminal incubation with an adenovirus (Ad.MMP-9). A subset was coincubated with Ad.TIMP-1. Mock virus served as a control. Plaques were analyzed histologically. In intermediate lesions, MMP-9 overexpression induced outward remodeling, as shown by a 30% increase in media size (p=0.03). In both intermediate and advanced lesions, prevalence of vulnerable plaque morphology tended to be increased. Half of MMP-9-treated lesions displayed intraplaque hemorrhage, whereas in controls and the Ad.MMP-9/Ad.TIMP-1 group this was 8% and 16%, respectively (p=0.007). Colocalization with neovessels may point to neo-angiogenesis as a source for intraplaque hemorrhage.
CONCLUSIONS: These data show a differential effect of MMP-9 at various stages of plaque progression and suggest that lesion-targeted MMP-9 inhibition might be a valuable therapeutic modality in stabilizing advanced plaques, but not at earlier stages of lesion progression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16306430     DOI: 10.1161/01.ATV.0000197795.56960.64

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  68 in total

1.  Leukocyte cathepsin C deficiency attenuates atherosclerotic lesion progression by selective tuning of innate and adaptive immune responses.

Authors:  Veronica Herías; Erik A L Biessen; Cora Beckers; Dianne Delsing; Mengyang Liao; Mat J Daemen; Christine C T N Pham; Sylvia Heeneman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-11-13       Impact factor: 8.311

Review 2.  Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases.

Authors:  Takayuki Shiomi; Vincent Lemaître; Jeanine D'Armiento; Yasunori Okada
Journal:  Pathol Int       Date:  2010-07       Impact factor: 2.534

Review 3.  Emerging applications of nanotechnology for the diagnosis and management of vulnerable atherosclerotic plaques.

Authors:  Shann S Yu; Ryan A Ortega; Brendan W Reagan; John A McPherson; Hak-Joon Sung; Todd D Giorgio
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2011-08-10

4.  IGF-1 has plaque-stabilizing effects in atherosclerosis by altering vascular smooth muscle cell phenotype.

Authors:  Jan H von der Thüsen; Keren S Borensztajn; Silvia Moimas; Sandra van Heiningen; Peter Teeling; Theo J C van Berkel; Erik A L Biessen
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

5.  The oxidized low-density lipoprotein receptor mediates vascular effects of inhaled vehicle emissions.

Authors:  Amie K Lund; JoAnn Lucero; Melissa Harman; Michael C Madden; Jacob D McDonald; Jean Clare Seagrave; Matthew J Campen
Journal:  Am J Respir Crit Care Med       Date:  2011-04-14       Impact factor: 21.405

6.  Monitoring plaque composition: is it worthwile?

Authors:  Arnoud van der Laarse; Ernst E van der Wall
Journal:  Int J Cardiovasc Imaging       Date:  2008-11-27       Impact factor: 2.357

7.  Non-significant left main disease; truly non-significant?

Authors:  E E van der Wall; J D Schuijf; J W Jukema; J J Bax; M J Schalij
Journal:  Int J Cardiovasc Imaging       Date:  2009-02-17       Impact factor: 2.357

8.  Coronary artery calcium screening: sufficient evidence for accurate risk assessment?

Authors:  Ernst E van der Wall; Joanne D Schuijf; J Wouter Jukema; Jeroen J Bax
Journal:  Int J Cardiovasc Imaging       Date:  2008-08-12       Impact factor: 2.357

9.  CT angiography; useful in non-selected outpatients?

Authors:  E E van der Wall; J D Schuijf; M J Schalij; J W Jukema; J J Bax
Journal:  Int J Cardiovasc Imaging       Date:  2009-01-15       Impact factor: 2.357

10.  CT angiography; no collateral damage.

Authors:  E E van der Wall; J D Schuijf; J W Jukema; M J Schalij; J J Bax
Journal:  Int J Cardiovasc Imaging       Date:  2009-01-22       Impact factor: 2.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.